logo

QNTM

Quantum BioPharma·NASDAQ
--
--(--)
--
--(--)
3.23 / 10
Netural

Fundamental measurement shows weak quality (3.2/10). Constructive metrics include Inventory turnover ratio and Interest coverage ratio (EBIT / Interest expense) (%), but Asset-MV presents a notable drawback. Final assessment: challenging.

Fundamental(3.23)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight24.85%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight1.60%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-2.07%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight19.95%
1M Return8.99%
PB-ROE
Value2.30
Score2/3
Weight26.71%
1M Return10.90%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.15%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.18%
1M Return0.10%
Asset-MV
Value-0.51
Score0/3
Weight13.48%
1M Return6.58%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.70%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight19.15%
1M Return8.80%
Is QNTM undervalued or overvalued?
  • QNTM scores 3.23/10 on fundamentals and holds a Fair valuation at present. Backed by its -257.97% ROE, 0.00% net margin, -0.57 P/E ratio, 2.15 P/B ratio, and 30.90% earnings growth, these metrics solidify its Netural investment rating.